Videos

Naval Daver, MD, explains the rationale for the phase II QUAZAR trial, which assessed the efficacy and safety of azacitidine in patients with acute myeloid leukemia.

First-Line PARPi Maintenance in Advanced Ovarian Cancer

Jeff P.&nbsp;<a>Sharman</a>, MD, discusses the safety profile of acalabrutinib that was demonstrated in&nbsp;<a href="https://www.targetedonc.com/conference/ash-2019/patients-with-cll-treated-on-the-elevatetn-trial-experience-improved-pfs-with-acalabrutinib"><strong>the phase III ELEVATE-TN trial</strong></a>. The trial&nbsp;&nbsp;evaluated acalabrutinib&nbsp;&nbsp;as a single agent or in combination with obinutuzumab versus obinutuzumab&nbsp;&nbsp;plus chlorambucil in patients with treatment-na&iuml;ve chronic lymphocytic leukemia.

Andre Goy, MD, discusses the results from a small clinical trial, which was presented at the 2019 American Society of Hematology Annual Meeting that he found particularly significant for the treatment of patients with relapsed/refractory mantle cell lymphoma.

Laura Michaelis, MD, discusses the next steps for research in the treatment of myelofibrosis following the addition of fedratinib to the armamentarium of JAK inhibitors.

Adam M. Brufsky, MD, PhD, FACP, discusses the TBCRC049 trial, which looks at the safety and efficacy of the tucatinib/trastuzumab/capecitabine combination to treat leptomeningeal metastases in HER2-positive breast cancer.

Transplant-Eligible Newly Diagnosed Multiple Myeloma

Outcomes in Newly Diagnosed Transplant-Ineligible Multiple Myeloma

Sara M. Tolaney, MD, MPH, discusses the results of the monarcHER trial, which examined adding the CDK4/6 inhibitor abemaciclib and endocrine therapy to trastuzumab versus trastuzumab plus chemotherapy in advanced hormone receptor-positive, HER2-positive breast cancer.

Rita Nanda, MD, discusses the IMpower130 trial in patients with metastatic triple-negative breast cancer who express PD-L1.